| Sinovac Wins Order for China’s National Immunization Program ChinaBio Today submits: Sinovac Biotech (NSDQ: SVA) was selected to supply its hepatitis A vaccine, Healive®, to the Beijing Expanded Program of Immunization [EPI]. Sinovac was selected one of the two suppliers and was allocated a greater share of the total purchase order. The decision was made by the Beijing CDC, which evaluated suppliers on the basis of several criteria, including product quality, service and price. The order was for 477,000 doses. As a point of reference, Healive orders for the third quarter of 2009 were almost 1 million.Complete Story » seekingalpha.com |
An Interview With Weikang Bio-Technology Group's VP Finance Ren Hu Zack Buckley submits:An interview with Weikang Bio-Technology Group Co. VP of Finance Ren Hu.Can you provide some background details of the company?Complete Story » seekingalpha.com |
For Therapists, No More Augusts Off Breaking tradition in large East Coast cities, therapists are staying in town and foregoing vacations in a tough economy, making it possible for patients to get appointments. online.wsj.com |
Small Cap Biotech Stocks: 7 Picks, 1 Big Concern Peter Navarro submits: Why I Like Biotech Stocks Biotech stocks are great to trade in a sideways market because they move mostly on science, not the economy.Biotech stocks have high risk but high reward – my 15-bagger of the year was Prolor Biotech (PBTH.OB), which went from 40 cents to 7 bucks and now trades on the Amex. How to Find Biotech Stocks Complete Story » seekingalpha.com |
FDA Extends Review of Merck Drug The U.S. Food and Drug Administration extended its review of German drug maker Merck's potential blockbuster Cladribine, feeding hope the treatment could be approved despite a negative opinion from European authorities. online.wsj.com |